DSIP
Reviewed
Short answer
DSIP, also called emideltide, is a peptide with nine amino acids. Small sleep studies from 1981 to 1992 used it through a vein. Some found short sleep changes. Others found little or no useful benefit. These studies do not prove that DSIP improves sleep or treats insomnia. DSIP is not an FDA-approved U.S. drug. A 2026 advisory vote did not add it to the current 503A list.
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Read the study findingsAlso known as Emideltide · Delta sleep-inducing peptide
Legal status Is DSIP legal? See the status table
Study and product details
What it is
DSIP, also called emideltide or delta sleep-inducing peptide, is a peptide with nine amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). Free base and acetate are different chemical forms. The 503A list is a U.S. list of bulk substances that may be used in some pharmacy compounding. A listed substance is not automatically an approved drug.
Type of peptide: Sleep-related peptide. This describes what the substance is or how it works. It does not show that it is safe, effective, or approved.
What has been studied?
- Limited: Research is too small or incomplete, or does not directly answer this question.
- Unclear: There is not enough reliable detail about the product or research to judge.
Small older human studies gave DSIP mainly through a vein and reported mixed sleep results. The studies do not establish a treatment benefit.
Some studies measured short-term sleep or hormone changes after use through a vein. They do not define how DSIP acts in every person or product.
FDA found no adequate long-term safety data and no human safety evidence for the proposed under-the-skin route. Product quality and immune-reaction risks remain uncertain.
FDA separates free base and acetate. Online products may not match either form or the material used in human studies.
Products with the same ingredient can differ.
The ingredient name does not tell you everything about a product. Check its other ingredients, its form, how it enters the body, and the use and people covered by the research or approval.
None identified in the United States.
- Small human studies of sleep
- Small human studies of withdrawal symptoms
Have a lab test report (COA) for a product sold under this name? Check what the report shows in 10 questions
Not sure if a product sold under this name is a prescription, compounded, or research-only vial? Sort it in 5 questions
What studies found
Small sleep studies from 1981 through 1992 tested DSIP, mostly through a vein. Some reported short sleep changes. Other controlled studies found little or no useful sleep benefit. One study measured a short-term change in a blood hormone, not better sleep. A few small studies also looked at narcolepsy or withdrawal symptoms.
These studies do not prove that DSIP improves sleep, treats insomnia, or treats opioid or alcohol withdrawal. The studies were small and used different designs. They do not show long-term benefit or safety. FDA's 2026 review found no adequate evidence for the proposed under-the-skin route and no long-term effectiveness data. It also found no adequate safety or toxicity record for the proposed use.
Which products do these findings apply to?
DSIP is also called emideltide. FDA separates emideltide free base from emideltide acetate, a salt form. These forms are not automatically the same as each other or as a product sold online. A product name does not prove its identity, contents, quality, or match to study material.
DSIP side effects and safety: what FDA has said
This page has no trial or drug-label side-effect table for DSIP. FDA keeps a page of bulk substances that may be risky when a pharmacy mixes (compounds) them. Here is what that page says about DSIP, in plain words.
FDA's page does not name specific side effects for DSIP.
- FDA found no safety information for the way it was proposed to be given. It says it cannot tell whether DSIP would harm people.
- The body's immune system may react against it. FDA says this risk depends on how it is given.
- Making it may leave unwanted peptide by-products in the product.
- It may be hard to confirm exactly what the main ingredient is.
These points come from FDA's review of compounded drugs. They are not a full list of side effects. Having no reports does not mean a product is safe.
Read FDA's exact words
Emideltide (DSIP): “Compounded drugs containing emideltide may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified safety-related information regarding emideltide for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.”
Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks , page dated .
Compare side-effect data across peptides
Report a side effect
You can report a suspected side effect to the FDA at 1-800-FDA-1088 or through FDA MedWatch . If a reaction feels serious, get medical care first.
FDA page checked .
Fact checks
6 statements checked. Read what the results mean.
“DSIP and emideltide refer to the same nine-amino-acid peptide.”
Yes. FDA's substance and briefing records use emideltide for DSIP and identify a nine-amino-acid sequence. This name match does not make free base, acetate, or online products equivalent.
- What this answer is based on
- Official record or product label
- Limits of this answer
- FDA substance identity records for DSIP and emideltide; this does not establish the identity or quality of an online product.
Sources for this fact check (2)
“DSIP is proven to improve sleep or treat insomnia.”
Small older human studies had mixed results. Some used controls, while others had important design limits. Together, they do not prove that DSIP improves sleep or treats insomnia.
- What this answer is based on
- No reliable studies showing this health result in people
- Limits of this answer
- Small human sleep studies using different designs, products, routes, and follow-up periods; the results do not establish a general treatment benefit.
Sources for this fact check (7)
“DSIP treats opioid or alcohol withdrawal.”
Small older studies examined withdrawal symptoms, but they did not establish that DSIP treats opioid or alcohol withdrawal. The findings do not support a general treatment claim.
- What this answer is based on
- No reliable studies showing this health result in people
- Limits of this answer
- The small human withdrawal studies reviewed; this does not establish a treatment benefit for withdrawal or any other condition.
Sources for this fact check (2)
Show 3 more fact checks
“DSIP is FDA-approved in the United States.”
FDA's briefing did not identify an FDA-approved U.S. drug containing emideltide. The current U.S. 503A list also does not list DSIP or emideltide. A substance record or a foreign or online product is not U.S. drug approval.
- What this answer is based on
- Official record or product label
- Limits of this answer
- United States approval and 503A status as reviewed August 30, 2026.
Sources for this fact check (2)
“The 2026 advisory vote added DSIP to the 503A list or approved it.”
The July 2026 committee vote was advisory. It did not itself change the 503A list or approve a drug. The current U.S. list does not show DSIP or emideltide, and no final FDA approval was identified in this review.
- What this answer is based on
- Official record or product label
- Limits of this answer
- The July 2026 advisory vote and United States 503A status as reviewed August 30, 2026; an advisory recommendation is not a final FDA decision or drug approval.
Sources for this fact check (3)
“Emideltide free base, emideltide acetate, and online DSIP products are interchangeable.”
FDA separates emideltide free base and emideltide acetate. An online product may have a different form, contents, or quality. The names alone do not show that these products are interchangeable.
- What this answer is based on
- Official record or product label
- Limits of this answer
- Chemical-form and product-identity comparisons; this is not a use or administration recommendation.
Sources for this fact check (2)
Questions people ask about DSIP
No. An advisory vote gives advice to the FDA. It was not final FDA approval or a final listing decision for DSIP. The vote did not add DSIP to the current 503A list, and it does not make an online or compounded product FDA-approved.
FDA's page on risky compounding substances says this about DSIP. It does not name specific side effects for DSIP. FDA found no safety information for the way it was proposed to be given. It says it cannot tell whether DSIP would harm people. The body's immune system may react against it. FDA says this risk depends on how it is given. Making it may leave unwanted peptide by-products in the product. It may be hard to confirm exactly what the main ingredient is. These points come from FDA's review of compounded drugs. They are not a full list of side effects.
Risks and safety limits
FDA identified important limits in the human safety and product-quality record. Free base, acetate, and online products may differ. This guide gives no dosing, administration, sourcing, product-selection, or treatment instructions.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed .Check the rules for athletes ↗Terms used in the studies
- peptide
- a short chain of amino acids
- amino acid
- a small building block that makes peptides and proteins
- route
- how the product enters the body
- mechanism
- how a substance may cause a body change
- biomarker
- a body or lab measurement, not automatically a health benefit
- outcome
- what the study measured
Read the sources
Show 15 sources
Review history
Initial brief reviewed FDA identity and compounding records, the July 2026 advisory-committee record, and small human studies of sleep, hormone changes, narcolepsy, and withdrawal symptoms.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.
Report a factual error